|1.||Cozzolino, Mario: 12 articles (04/2014 - 06/2003)|
|2.||Wu-Wong, J Ruth: 11 articles (04/2015 - 03/2004)|
|3.||Thadhani, Ravi: 10 articles (11/2014 - 08/2010)|
|4.||Nakane, Masaki: 9 articles (02/2013 - 01/2006)|
|5.||Slatopolsky, Eduardo: 8 articles (06/2015 - 06/2003)|
|6.||Andress, Dennis L: 8 articles (09/2013 - 07/2005)|
|7.||Amdahl, Michael: 7 articles (01/2014 - 04/2003)|
|8.||Williams, Laura A: 7 articles (08/2012 - 01/2006)|
|9.||Ferder, Leon: 6 articles (08/2015 - 01/2009)|
|10.||Sprague, Stuart M: 6 articles (09/2014 - 04/2003)|
01/01/2014 - "In conclusion, 52 weeks of treatment with oral paricalcitol (1 μg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD. "
01/01/2011 - "Treatment with paricalcitol is effective in controlling secondary hyperparathyroidism in non-dialysed patients with a wide safety margin."
01/01/2013 - "Previous studies have demonstrated the safety and efficacy of using Paricalcitol for the treatment of secondary hyperparathyroidism (SHPT) in patients on dialysis. "
12/01/2005 - "In three double-blind, randomized, placebo-controlled studies to evaluate the safety and efficacy of oral paricalcitol, 220 CKD stage 3 and 4 patients with secondary hyperparathyroidism (SHPT) were randomized to oral paricalcitol (N= 107, mean dose 9.5 microg/week) or placebo (N= 113) and followed for up to 24 weeks. "
01/01/2014 - "Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects."
|2.||Hypercalcemia (Milk Alkali Syndrome)
06/01/2013 - "Paricalcitol was discontinued in four patients due to hypercalcuria/hypercalcemia and in one for preference. "
06/01/2013 - "Paricalcitol was well-tolerated with no instances of hypercalcemia grade 2 or greater. "
03/01/2012 - "Compared with the control group, the RR for hypercalcemia associated with paricalcitol use was 2.25 (95% CI, 0.81-6.26; P=0.12). "
02/15/2012 - "Episodes of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group. "
06/01/2007 - "Two consecutive 30% decreases from baseline in iPTH levels and safety of paricalcitol, including hypercalcemia and increase in Ca x P product. "
01/01/2013 - "In this study, we investigated the effects of paricalcitol on inflammation and epithelial-mesenchymal transition (EMT) after HHE-induced renal tubular epithelial cell injury. "
04/01/2015 - "We studied effects of paricalcitol compared to placebo on endothelial function and markers of inflammation and oxidative stress in patients with T2DM and CKD. "
02/07/2014 - "These results demonstrate that pre-treatment with paricalcitol has a renoprotective effect in ischemic AKI, possibly by suppressing TLR4-NF-κB mediated inflammation."
01/01/2013 - "These results show that paricalcitol attenuated HHE-induced renal tubular cell injury by suppressing inflammation and EMT process through inhibition of the NF-κB, TGF-β/Smad, and β-catenin signaling pathways."
01/01/2013 - "Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells."
09/01/2014 - "Suppression of PTH may be a useful strategy for skeletal improvement in XLH patients with hyperparathyroidism, and paricalcitol appears to be an effective adjunct to standard therapy in this setting. "
06/01/2013 - "Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial."
06/01/2013 - "One-year posttransplant, 29% of paricalcitol-treated subjects had hyperparathyroidism compared with 63% of untreated patients (p = 0.0005). "
01/01/2003 - "Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up."
06/01/2013 - "Oral paricalcitol is effective in decreasing posttransplant hyperparathyroidism and may have beneficial effects on renal allograft histology."
01/01/2013 - "Paricalcitol is effective in lowering PTH in patients with CKD not yet on dialysis and is also effective in lowering proteinuria in diabetic CKD patients. "
01/01/2011 - "Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury."
01/01/2013 - "Our study shows an important reduction in proteinuria with a low dose of oral paricalcitol in CKD, that is particularly robust with baseline proteinuria between 1-3 g/d."
08/01/2012 - "Peritoneal kinetic studies were performed before and after paricalcitol, measuring also ultrafiltration/ day, peritoneal protein losses and proteinuria. "
10/01/2009 - "Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial."
|3.||Parathyroid Hormone (Parathormone)
|4.||Calcitriol Receptors (Calcitriol Receptor)
|10.||1 alpha-hydroxyergocalciferol (doxercalciferol)
|1.||Renal Dialysis (Hemodialysis)
|3.||Homologous Transplantation (Allograft)
|4.||Transplantation (Transplant Recipients)